Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics develops and commercializes medicines for children and adults with rare disorders, with a life-science business focused on clinically differentiated therapies in areas including neurology and metabolism. Company news commonly covers product revenue, commercial launch activity, financial guidance, investor presentations, and updates from its rare-disease development portfolio.
Recurring developments include Sephience™ (sepiapterin) launch and revenue updates, clinical and regulatory disclosures involving votoplam, vatiquinone and Translarna™ (ataluren), and partnership-related program responsibilities. PTC also reports governance changes and Nasdaq inducement equity grants tied to employee compensation.
PTC Therapeutics (NASDAQ: PTCT) reported a 39% growth in its Duchenne muscular dystrophy (DMD) franchise, with third-quarter net product revenue reaching $114 million. Total revenues increased to $138.7 million, compared to $118.4 million in Q3 2020. The company anticipates full-year DMD franchise revenues between $400 and $420 million, adjusting previous guidance. However, net losses rose to $133.6 million from $69.7 million year-on-year, and cash reserves decreased to $867.9 million. PTC continues advancements across its clinical pipeline with several ongoing trials.
PTC Therapeutics will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Nov. 9, 2021, at 8:00 a.m. ET. The presentation will be accessible via a live webcast on the company's investor site and archived for 30 days post-event. PTC focuses on developing innovative treatments for rare disorders, emphasizing a strong scientific foundation and global commercial capabilities to meet unmet patient needs.
PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced that Brazil's ANVISA has approved the expansion of Translarna™ (ataluren) to include children aged 2 to 5 with nonsense mutation Duchenne muscular dystrophy (Duchenne). This broadens the prior indication of 5 years and older, allowing earlier treatment that may preserve muscle function and slow disease progression. Translarna is the sole treatment targeting the underlying cause of Duchenne due to a nonsense mutation and is licensed in the EEA for ambulatory patients aged 2 and older.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on Oct. 28, 2021, at 4:30 p.m. ET to report its third quarter financial results and provide a business update. Investors can join the call by dialing (877) 303-9216 in the U.S. or (973) 935-8152 internationally, using passcode 8574103. A live webcast will be available on the company's investor website, with a replay accessible two hours post-call and archived for 30 days. PTC focuses on developing innovative treatments for rare disorders, backed by a robust product pipeline.
Summary not available.
PTC Therapeutics announced that Tegsedi® (inotersen) has received Category 1 classification from Brazil's CMED, allowing for pricing aligned with international standards. Approved by ANVISA for treating hATTR amyloidosis, Tegsedi is the first antisense medicine available in Brazil and is expected to improve the quality of life for approximately 5,000 patients in the country. The drug has shown significant efficacy in clinical studies, enhancing patient outcomes while enabling self-administration.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced the approval of non-statutory stock options for 51,400 shares and 18,790 restricted stock units (RSUs) on Sept. 22, 2021, for 47 new employees. The stock options have an exercise price of $39.29, equal to the closing stock price on Sept. 24, 2021. The options vest over four years, with 25% vesting on the first anniversary. The RSUs also vest over four years with annual vesting. This is part of the company's strategy to attract talent in alignment with NASDAQ Listing Rule 5635(c)(4).
PTC Therapeutics, Inc. (NASDAQ: PTCT) presented five-year results on its gene therapy, PTC-AADC, showing significant improvements in children with AADC deficiency, a severe neurological disorder. Treated children displayed enhancements in motor and cognitive skills, with many achieving milestones previously unattainable. A notable reduction in respiratory infections from 2.4 episodes annually to 0.3 was reported. The therapy is under review by the European Medicines Agency and a Biologics License Application is expected for submission to the U.S. FDA by year-end 2021.
PTC Therapeutics (NASDAQ: PTCT) will host a conference call on September 23, 2021, at 8:00 a.m. ET to discuss positive results from the PTC518 Phase 1 study in healthy volunteers. Key findings include significant lowering of HTT mRNA and protein levels, confirming PTC518's capacity to penetrate the blood-brain barrier. The company also plans to initiate the Phase 2 study in Huntington's disease patients by year-end. Currently, there are no approved therapies addressing this debilitating condition.
PTC Therapeutics (NASDAQ: PTCT) presented real-world findings from the STRIDE registry, revealing that Translarna (ataluren) delays loss of ambulation by over five years in boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) compared to standard care. The analysis demonstrated a median age of 17.9 years for loss of ambulation in treated boys, versus 12.5 years in those receiving standard care. Additionally, lung function decline was delayed by 1.8 years. The safety profile remains consistent with previous data, emphasizing Translarna's significant impact on enhancing patients' quality of life.